ORIGINAL RESEARCH article
Front. Oncol.
Sec. Surgical Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1602933
Predicting resectability after neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer: a single center, retrospective trial
Provisionally accepted
Florian Schepp1,2*
Sebastian Hempel1,2
Felix Bechtolsheim1,2Felix Merboth1,2Olga Radulova-Mauersberger1,2
Christian Teske1,2Nicolas Mibelli1,2Lena Seifert1,2Jürgen Weitz1,2Marius Distler1,2
Florian Oehme1,2*- 1National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Dresden, Lower Saxony, Germany
- 2Clinic and Polyclinic for Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, Lower Saxony, Germany
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background/Objectives: Pancreatic ductal adeno carcinoma (PDAC) in its borderline resectable (BR) stage often limits the possibility of complete resection, currently the only potential path to a cure. Neoadjuvant chemotherapy seeks to downsize tumors, thereby increasing the chances of achieving an R0 resection. However, accurately predicting resectability following such treatment remains challenging. This study aims to identify and evaluate potential biomarkers that may improve preoperative assessment of tumor resectability during exploratory laparotomy, thereby minimizing the incidence of futile surgical interventions and their associated morbidity in patients with non-resectable malignancies. Methods: We conducted a retrospective analysis of all patients who underwent exploratory laparotomy following neoadjuvant chemotherapy at the Department of Visceral, Thoracic, and Vascular Surgery, University Hospital Dresden, between 2011 and 2022. Employing a propensity score matching, we compared patients with resectable and unresectable pancreatic cancer. The primary endpoint was to evaluate preoperative parameters for predicting resectability status. Results: This study included initially 134 patients with neoadjuvant treated BR PDAC who underwent exploratory laparotomy. Among them, 100 (74.6%) underwent curative intended resection, and 34 (25.4%) had an explorative laparotomy only. After Propensity Score Matching we found that a pre-chemotherapy CA 19-9 Value ≤ 450 U/ml (OR 2.9; 95% CI: 1.04 – 8.53, p = 0.04), a pre-operative CA19-9 value of ≤ 105 U/ml (OR 13.9; 95% CI: 3.88 – 49.7, p = 0.001), and a pre - to post-chemotherapy CA19-9 ratio of ≤ 15% (OR 9; 95% CI: 2.48 – 32.7, p = 0.001) raised the odds for resectability. Further, if the combination of a preoperative CA 19-9 ≤ 105 U/ml and a pre - to post-chemotherapy CA19-9 ratio of ≤ 15% was present, the resectability rate increased up to 93%, compared to 30% when both parameters were above the threshold. This specific constellation was a significant predictor (OR 63; 95 % CI: 7.84 – 506, p = 0.001) for curative resectability. Conclusions: Our data highlight not only the significant role of the preoperative CA19-9 value and the pre-to post-chemotherapy CA19-9 ratio but, even more importantly, emphasize the critical impact of the combination of these two parameters on the resectability of BR-PDAC.
Keywords: prediction of resectability, Carbohydrate antigen 19-9, CA19-9, Pancreatic Cancer, Resectability, Neoadjuvant chemotherapy
Received: 30 Mar 2025; Accepted: 05 Sep 2025.
Copyright: © 2025 Schepp, Hempel, Bechtolsheim, Merboth, Radulova-Mauersberger, Teske, Mibelli, Seifert, Weitz, Distler and Oehme. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Florian Schepp, National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Dresden, 01307, Lower Saxony, Germany
Florian Oehme, Clinic and Polyclinic for Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Dresden, 01307, Lower Saxony, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.